Timothy Scannell Will Become Chairman of the Board BILLERICA, Mass. --(BUSINESS WIRE)--Sep. 10, 2018-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced
BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 28, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at two upcoming investor conferences in New York City
BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 16, 2018-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced it will showcase its recently FDA cleared Omnipod
Full Year 2018 Expected Revenue Growth Revised to 18% to 21% Third Quarter Expected Revenue Growth of 19% to 24% BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 2, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ®
LONDON --(BUSINESS WIRE)--Jul. 12, 2018-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced that it has partnered with Glooko ® , Inc.
BILLERICA, Mass. --(BUSINESS WIRE)--Jul. 11, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the second quarter of 2018
BILLERICA, Mass. & LONDON --(BUSINESS WIRE)--Jul. 9, 2018-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced it has entered into a partnership with
Tubeless, Waterproof * Insulin Pump and Wireless, Handheld Personal Diabetes Manager Make Switching from Multiple Daily Injections to Pump Therapy Much Easier BILLERICA, Mass. & ONTARIO, Canada --(BUSINESS WIRE)--Jul. 3, 2018-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the
BILLERICA, Mass. & LONDON --(BUSINESS WIRE)--Jul. 2, 2018-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced as of July 1 , it has assumed direct commercial
Omnipod ® Horizon ™ System Significantly Improves Glycemic Control in Patients with Type 1 Diabetes BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 24, 2018-- Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management
DASH System Features Sleek, Color Touch-Screen Handheld Personal Diabetes Manager, Bluetooth-Enabled, Waterproof 1 , Tubeless Pump and Suite of User-Friendly Mobile Applications No-Cost Personal Diabetes Manager with Purchase of Pods BILLERICA, Mass. --(BUSINESS WIRE)--Jun.
BILLERICA, Mass. --(BUSINESS WIRE)--May 29, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at the William Blair & Company 38 th Annual Growth Stock
Increases Full Year 2018 Expected Revenue Growth to 22% to 25% on Strength in Global Omnipod; Introduces Second Quarter Expected Revenue Growth of 18% to 22% BILLERICA, Mass. --(BUSINESS WIRE)--May 3, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless
High-Caliber Team in Place Throughout Key Geographies Partnerships Established with Experienced European Companies for Customer Care and Logistics BILLERICA, Mass. & LONDON --(BUSINESS WIRE)--May 3, 2018-- Insulet Corporation (NASDAQ:PODD) ( Insulet or the Company), the leader in tubeless insulin
